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1. Introduction
Patients suffering from end-stage renal disease (ESRD) treated with renal replacement therapy
is a continuously growing population [1–3]. Hemodialysis is the most preferable modality
among them [4], making a suitable permanent vascular access (VA) vital for their treatment.
The ultimate purpose is the successful creation of a well-functioning, long-lasting VA, capable
of delivering adequate dialysis to the patient with the minimum of complications under its
appropriate management. In the last years in this field of nephrology, very few changes have
taken place. Three types of permanent VA are in use, arteriovenous fistula (AVF), arteriove‐
nous grafts (AVGs), and cuffed central venous catheters (CVCs). Long-lasting survival,
adequate blood flow, and low complications rate are necessary characteristics of them. Native
forearm AVF best fulfills this criteria and is the first choice of VA, the first native arteriovenous
fistula (AVF) described in 1966 by Brescia and Chimino [5]. The second choice is upper arm
AVF, followed by AVG and last one cuffed CVC [6–8]. Vascular access dysfunction is respon‐
sible for 20% of dialysis patients’ hospitalizations in the USA [9], making it one of the most
important causes of morbidity [10], while the annual cost of VA creation and maintenance is
over 1 billion dollars yearly [11], with arteriovenous graft (AVG) cost be more than fivefold
higher than AVF [12]. Thus, VA is called the “Achilles’ heel” of hemodialysis [13].
2. History of vascular access
In 1924, Haas [14] carried out the first hemodialysis treatment in humans using glass needles
in radial and cubital vein. In 1943, Kolff used venipuncture needles in the femoral artery and
vein [15, 16]. Kolff’s [17] twin-coil kidney made regular hemodialysis treatments possible in
1950s, making the need of a safe, reliable, long-lasting VA more imperative.
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Aubaniac [18], in 1952, described the puncture of subclavian vein as a VA, while, in the 1960s,
Dillard, Quinton, and Scribner [19], based on Alwall’s experience, developed arteriovenous
Teflon shunt inserted into radial artery and cephalic vein. Flexible silicon rubber replaced later
Teflon. Based on Seldinger’s technique, Shaldon inserted catheters into femoral artery and vein
for dialysis sessions in 1961 [20, 21]. Vessels in different sites were used, over time, including
the subclavian, jugular, and femoral vein.
Cimino and Brescia [22] described, in 1962, a “simple venipuncture for hemodialysis.” Fogarty
et al. [23] invented, in 1963, a special designed catheter for thrombectomy and embolectomy
with an inflatable balloon at its distal tip. In 1965, the first AVF was created, and 14 more in
1966 when Brescia, Cimino, Appel, and Hurwich published their paper [24]. Sperling [25], in
1967, created an end-to-end anastomosis in the forearm, between radial artery and cephalic
vein, in 15 patients, whereas Appell did side-to-side anastomosis. End-to-end anastomosis
usually is not the first choice of AVF due to high risk of steal syndrome in aging, diabetic
patients of dialysis, but it remains a useful option in revision procedures, although it is
correlated with higher mortality risk from infections [26].
Nowadays, artery side-to-vein anastomosis seems to be a standard procedure [27], which
began from Rohl et al. [28] in 1968. Girardet et al. [29] and Brittinger et al. [30] in 1970 described
their experience with AVG between femoral vein and artery and subcutaneously fixed
superficial femoral artery for chronic HD. Brittinger et al. [31] were the first to implant a plastic
valve as a vascular access in an animal model, but unfortunately, their efforts did not proceed
to a human one. In the early 1970s, Buselmeier et al. [32] developed a U-shaped silastic
prosthetic AV shunt with either one or two Teflon plugged outlets, which communicated to
the outside of the body. The U-shaped portion could be totally or partially implanted subcu‐
taneously. Subsequently, pediatric hemodialysis patients were extremely favored by this
procedure. In 1976, Baker [33] presented expanded PTFE grafts in 72 hemodialysis patients.
In the subsequent years, several publications indicated the benefits and the shortcomings of
the prosthetic material in question, remaining the primary choice of graft for hemodialysis VA
to date. The same year, two authors, Mindich and Dardik, had worked with a new graft
material: the human umbilical cord vein [34, 35]. Regrettably so, this material did not succeed
in becoming a revolutionary graft material due to its inadequate resistance against the trauma
of repeated cannulations and their complications (aneurysm and infection). After the subcla‐
vian route for hemodialysis access was firstly introduced by Shaldon in 1961, it was further
processed in 1969 by Josef Erben, using the intraclavicular route [36]. In the next 20 years or
so, the subclavian vein was the preferred access for temporary vascular access by central
venous catheterization. Today, due to phlebographic studies revealing a 50% stenosis or
occlusion rate at the cannulation site, subclavian route has been discarded. Subclavian stenosis
and occlusion predispose to edema of the arm, especially after creation of an AV fistula [37].
The first angioplasty described by Dotter et al. [38], who introduced a type of balloon, was
immensely conducive to the resolution of one of the most significant predicaments in vascular
surgery and vascular access surgery.
In 1977, Gracz et al. [39] created the “proximal forearm fistula for maintenance hemodialysis,”
a variant of an AV anastomosis. An adjustment of this AVF became quite significant in the old,
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hypertensive, and diabetic patients on the grounds that it allows a proximal anastomosis with
a low risk of hyper circulation [40]. In 1979, Golding et al. [41] developed a “carbon transcu‐
taneous hemodialysis access device” (CATD), commonly known as “button,” as a blood access
not requiring needle puncture. As a procedure of the third choice, these devices were expensive
and never gained widespread acceptance. Shapiro et al. [42] described another type of
“button,” a device similar to that developed by Golding.
3. Classification of vascular access
Nowadays, and thanks to all above efforts, nephrologists have the ability to choose the most
suitable VA for their patients depending on special needs of each one. Based on expected half-
life, the first demarcation is of permanent and temporary VAs [43]. Long-term or permanent
VAs are called the ones with an expected half-life of more than 3 years, and mainly include
AVF [13] and PTFE AVG. VAs with expected half-life of less than 90 days are called temporary
VAs and basically are noncuffed double lumen catheters and arteriovenous shunts. The VAs
with half-life between the above categories (90 days to 3 years) are the mid-term VA containing
tunneled cuffed catheters, port devices and external and internal shunts.
3.1. Acute hemodialysis vascular access
Acute hemodialysis is a lifesaving treatment, which needs a VA in order to be carried out.
When a permanent VA is not available, the preferred and currently available VA for acute
hemodialysis is cuffed tunneled and noncuffed nontunneled hemodialysis catheters (Figures
1–5). The reason is that they can be used immediately and placed relatively easily. For catheter
insertion, a modified Seldinger guide wire technique is used, preferably with ultrasound
guided assistance for minimizing acute placement complications [44, 45].
Figure 1. Noncuffed in jugular double lumen catheter.
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Figure 2. Cuffed tunneled in jugular double lumen catheter.
Figure 3. Permanent cuffed jugular catheter.
Figure 4. Acute noncuffed jugular catheter.
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Figure 5. Femoral noncuffed catheter.
The most used and feasible are the noncuffed nontunneled catheters with easy insertion and
availability for immediate use. They have some specific technical characteristics; they are made
of polymers inelastic at room temperature, facilitating the insertion, but unstiffening at inner
body temperature in order to be atraumatic for the vessels. The distance between the inflow
and the outflow tip of the catheter must be at least 2 cm to lessen recirculation [46].
Central veins such as jugular or femoral can be used as insertion routes of these catheters [47].
Subclavian typically is an option, but due to its higher incidence of complications, such us lung
injury, it is used when the others insertion sites are not feasible.
The National Kidney Foundation Dialysis Outcomes Quality Initiative (K/DOQI) 2006
guidelines recommend the radiographical identification of tip placement and any potential
complications before catheter use or anticoagulation treatment [48]. Subclavian vein should
be avoided for catheter insertion due to high frequency of stenosis and thrombosis.
There are restrictions concerning the use of these catheters such as the blood flow with a
maximum pump speed of 300 ml/min, although actual blood flow tops at 250 ml/min, catheters
for insertion in femoral vein should be no less of 18 to 25 cm long to minimize recirculation [49,
50]. Their insertion site determines their life use, with the ones in internal jugular vein be
suitable for use for about 2 to 3 weeks, while in femoral vein are used for 3 to 7 days in
bedridden patients and for a single treatment in ambulatory patients [51]. Nevertheless,
according to KDOQI guidelines, the life use of noncuffed, nontunneled catheters must be of a
week or less; when hemodialysis treatment will be required for a longer period, the placement
of cuffed, tunneled catheters is suggested [48]. Especially in hospitalized patients, triple lumen
catheters are placed, using the third lumen for intravenous drugs and fluid administration and
for blood drawing. It seems that two and three lumen catheters have similar blood flow and
inflections incidence [52]. The leader cause for catheter removal is infectious complications.
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3.2. Permanent vascular access
Taking patient-dependent factors into consideration, such as life expectancy, comorbidities,
the status of the venous and arterial vascular system, is very important in order to prescribe
the appropriate access. Each type of access, such as arteriovenous fistula (AVF), arteriovenous
graft (AVG) or TC, has a different effect on circulatory system, and this should be taken into
consideration. Also, the duration of their functionality and the risk for infection and thrombosis
are important factors to consider. Each type of surgical anastomosis has advantages and
disadvantages [53]. Also, it seems that the advantages of an AVF attempt strategy lessened
considerably among older patients, particularly women with diabetes, reflecting the effect of
lower AVF success rate and lower life expectancy, suggesting that vascular access-related
outcomes may be optimized by considering individual patient characteristics [54]. The
American Association for Vascular Surgery and the Society for Vascular Surgery, in 2002, for
better consultation and understanding between physicians and registration of VA set VA
reporting standards in which three components should be listed, structure (autogenous,
prosthetic), position and alignment (loop, direct, etc.) [55]. Risk factors such as female gender,
age, diabetic nephropathy, dialysis initiation via CVC and inability of VA maturation before
HD initiation are responsible for the majority of VA failure. Repetitive VA failures are risk
factor for mortality [56]. It seems that early referral to nephrologist and patient’s education
leads to initiation of dialysis with permanent VA, better metabolic and clinical situation, lower
long-term morbidity and higher 2-year survival [57–61]. It is of benefit to the patient to begin
hemodialysis treatment via a functional AVF than with a TC [62–64]; however, grafts are a
better alternative to TCs, when AVF is not feasible [65]. Patients with bilateral central vein
stenosis often require more than one vascular access modality to achieve a “personal access
solution.” Native long saphenous vein loops provided the best long-term patency. Expedited
renal transplantation with priority local allocation of cadaveric organs to patients with
precarious vascular access provides a potential solution [66]. Patients who received either
femoral AVG or HeRO VA device experience poor access patency. ESRD patients who receive
either of these procedures appear to be at the end stage of available access options [67].
3.2.1. Arteriovenous fistula
The first choice of VA is AVF, for its longevity and low morbidity and mortality rates [68, 69],
low complication incidence for infection (one-tenth of AVGs) and thrombosis (one-sixth of
AVGs) [70, 71]. AVFs’ primary patency rates at 1 year vary considerably between USA and
Europe, with reports from the USA that include diabetic patients be as low as 40–43% [72, 73].
From the study of 748 AVFs in diabetic patients over 5 years, Konner et al. showed a primary
patency rate of 69–81% [74], while Chemla et al. had a rate of 80% at 22 months in 552 radio‐
cephalic AVFs in 153 patients over a 4-year period [75]. Hemodialysis patients with AVF have
lower mortality and that seems to be attributed not only to decreased incidence of infections
and VA dysfunctions but also to other factors, such as LVEF increase and blood pressure and
arterial stiffness reduction, as Korsheed et al. [76] showed.
Based on the way of their creation, three types of AVFs can be identified. The first type belongs
to the AVFs where an artery and a vein are connected in their natural position, with a side-to-
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side or side-artery-to-vein-end anastomosis. In the second type, a vein is connected to an artery
in end-to-side form, after its metathesis, to connect a further distance or surface the vein to
facilitate cannulation; a tunnel creation is required for vein’s new positioning. When a vein is
connected to an artery end-to-end after it is removed from its anatomical location, we have the
third type of AVF [77] (Figures 6–9). The end-to-end technique is abandoned nowadays since
it leads to advanced risk for ischemia and thrombosis. Vein end to artery side anastomosis is
the most common technique. The first option for the primary AVF is the radial-cephalic. Distal
forearm ulnar-basilic has similar secondary patency rate to it and is the best alternative when
the first one is not feasible [78]. Stenosis due to technical problems like false surgical cut of
vein leads to dysfunctional VA. Complications such as heart failure or steal syndrome may
result from a more proximal, big arterial anastomosis [77]. Local anesthesia is usually effective
for AVF creation, and the morbidity of the procedure is low. AVF requires time after its creation
for maturation before cannulation for at least 14 days according to DOPPS (Data from the
Dialysis Outcomes and Practice Patterns Study). During the period of maturation, the blood
flow and the vessel size increase over time in 8–12 weeks, and the initial blood flow is in a
range of 200–300 ml/min [64].
Figure 6. Forearm AVF.
Figure 7. Side-to-side forearm AVF.
The placement of AVFs should be initiated when the patient reaches CKD stage 4, or within 1
year of the anticipated start of dialysis. In their recent study, Hod et al. [79] suggested that
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creating AVF more than 6 to 9 months before initiating dialysis in elderly may not associate
with better AVF success rate. In order to increase the possibilities of a well-functioning AVF’s
creation and to minimize the complication, a physical examination must be done prior to
procedure to identify any differences in blood pressure between the upper extremities [80] and
the presence or lack of a well-developed palmar arch to avoid steal syndrome in case of using
the dominant artery for AVF creation [81].
Additional information before the creation of AVF can be given with ultrasound of the vessels;
their diameter is closely correlated with surgery success with a size of 2 mm and more leads
with fruitful maturation [80], in contrast of a size of 1.6 mm and less, which predispose to
failure [82]. The upper extremity AVF is the preferred access for hemodialysis, the duplex
ultrasound identifies suitable arteries and veins for its successful creation, while early
detection and intervention can save the fistula when complications occur [83]. Uzun et al. [84]
showed that autologous saphenous vein can be preferably chosen as a prosthetic hemodialysis
access graft due to its higher primary and secondary patency and lower complication rate and
cost when compared with PTFE grafts. According to the vascular access guidelines of KDOQI,
a well-functioning AVF has blood flow over 600 ml/min, with a diameter greater than 6 mm,
and is lying less than 6 mm from the surface in a depth between 5 and 10 mm. When an AVF’s
maturation progresses successfully, then rapidly after surgery blood flow increases from
baseline values of 30 to 50 ml/min, reaching 200 to 800 ml/min within 1 week; after 8 weeks,
blood flow is over 480 ml/min [85, 86]. The AVFs must be evaluated 4–6 weeks after placement;
experienced examiners (e.g., dialysis nurses) can identify nonmaturing fistulas with 80%
accuracy [87]. Patients with newly placed AVF are advised for hand squeezing exercises to
increase the rate of fistula maturation, such as squeezing a ball, bicep curls, and finger tips
Figure 8. End-to-end forearm AVF.
Figure 9. Side-to-end forearm AVF.
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touches resulting to fistulae dilation [88, 89]. Far Infrared therapy, which is a form of heat
therapy, has been implicated in improvement of endothelial function and hemodynamics in
coronary arteries, probably through up-regulating endothelial nitric oxide synthase (eNOS)
expression in arterial endothelium, leading to improved cardiac function in patients with
chronic heart diseases. Repeated leg hyperthermia using FIR has been shown to reduce
oxidative stress in bed-ridden type II diabetics and may positively influence the complex
process of AVF maturation, improving both primary and secondary patency rates [90, 91].
Jennings et al. [92] published a trial, which showed that Venous Window Needle Guide, a
subcutaneously placed hemodialysis cannulation device, is safe and effective in facilitating
AVF cannulation for patients with an otherwise mature but noncannulatable access. Strozecki
et al. described a case report of a 65-year-old female patient who had several hemodialysis
sessions by cannulation of dilated collateral abdominal veins with dialysis needles, as an
unconventional vascular access for HD in case of central vein occlusion [93]. Humerobasilic
and radiocephalic AVF are the two VA types with the most functioning longevity, although
in radiocephalic AVF, there is high initial failure rate [94]. It is the preferable VA due to its
longevity, low incidence of complications, and easy cannulation [95–97]. In case of failure of
radiocephalic AVF creation, the second most preferable VA is brachiocephalic AVF, which
comes first in diabetic patients, in whom the inadequacy of vessels for radiocephalic AVF is
usually found [98] with a reported 4-year patency of 80% [99]. According to a study of
Rondriguez et al., brachiocephalic AVF has a lower survival than radiocephalic. Four years
after its creation, just over 50% of the patients have patent AVF and about 30% after 8 years.
Failure at first VA increases the risk for following failure, while successful development of the
first VA, at about 60% of patients, does not lead to subsequent failure. Diabetes and female
gender seem to be risk factors to VA failure [94].
3.2.2. Arteriovenous graft
In the USA, AVGs (Figures 10–12) are the most common type of VA that is used for hemo‐
dialysis [100]. However, they last less than AVFs and have more complications such as
infections and thromboses [70]. Recent technological advances using tissue-engineered AVGs
have shown promise for patients receiving hemodialysis and their potential to provide an
attractive, viable option for vascular access [101]. Grafts present a second choice of VA when
AVF is not possible to be performed because of vascular problems [102]. AVGs have lower
risk of nonmaturation in lower time [103]. They can be placed in the forearm, the upper arm
and the thigh, when upper-extremity options are exhausted [104] and they can have a straight,
curved or loop configuration. Axillary loop arm graft yields acceptable early patency rates in
specific patients with vascular problems [105]. Another advantage is that AVGs may offer a
large surface for cannulation. Some types of AVGs such as PTFE AVGs can be cannulated
immediately after their placement, according to some studies, although it is preferable to wait
for about 2 to 3 weeks for the first cannulation [106, 107]. However, the usual time for a
functional graft is 2 to 3 weeks in order to reduce the post surgical edema and the perigraft
hematoma and seroma [108]. Karatepe et al. [109] presented a novel polycarbonate urethane
nanofabric graft, produced by electrospinning technology, which had self-healing features that
avoid seroma formation and allow puncturing within 48 hours. It had good 12-month primary
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and secondary patency rates and substantially lowers infection rates. Early experience with
GORE Acuseal is encouraging with patency and bacteremia rates at least comparable to
standard polytetrafluoroethylene grafts, permitting cannulation within 24 hours of insertions
and line avoidance in the majority of patients [110].
Figure 10. Upper arm AVG.
Figure 11. Looped forearm AVG.
Figure 12. Straight femoral AVG.
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3.2.3. Tunneled hemodialysis catheter
TCs (Figures 2 and 3) have higher mortality risk than AVFs or AVGs; thus, they are used
when the creation of the latter is not feasible [111]. There are several reasons that lead to
the inability for AVF or AVG creation, such as multiple vascular surgeries, which lead to
vascular thrombosis, or when patients have severe peripheral vascular disease or very low
cardiac output.  TCs are more frequently encountered in pediatric and very old patients.
They can also be used as a bridge until AVF or AVG maturation [111]. Their use remains
very high during the first  year  of  HD care and is  associated with high mechanical  and
infection rates [112]. The incidence of AVFs has been effectively increased since the “fistula
first”  has  been  developed  [113],  although  it  is  accompanied  with  an  increase  in  TCs,
especially those used as a bridge until the maturation of an AVF [100]. Nonetheless, DOPPS
shows an increasing use of TCs for the period 1996 to 2006 in many countries [114], which
is in accordance with our data of 2011, which showed increased prevalence of TCs in female
hemodialysis patients [115]. It is also signified that it is more likely for a patient to have
permanent VA (AVF or AVG) than TC if he is at a center with experienced vascular surgery
department successfully creating permanent VA in diabetic, older women and early AVF
cannulation practice (within 4 weeks from its formation) [114].
They do not last as much as the others types of VA, and they have higher complication rates
such as infections. There are studies revealing that CVCs are colonized within the first 10 days
of placement; however, the catheter’s lumen colonization does not equal to positive blood
cultures or clinical signs of bacteremia [116]. The guide-wire change or the complete removal
of catheter does not affect the outcome of the infection treatment [117]. Power et al. [118] with
their study of 759 TCs showed that the appropriate management of catheters can give
functional and complication results similar to AVGs. In their study, survival rates were 85%,
72%, and 48% at 1, 2, and 5 years, respectively, while the infection rate was 0.34 per 1000
catheter-days. Although earlier studies showed a lower risk of catheter-related bloodstream
infections with internal jugular TCs compared to femoral, recent studies show no difference
between the three sites [119, 120].
Transhepatic hemodialysis catheters seem to be a viable alternative option with low morbidity
rates [121]. Another safe and effective long-term access is translumbar inferior vena cava [122].
Retrograde femoral vein catheter insertion is a newly applied lifesaving HD vascular access
approach for selected ESRD patients with no available HD vascular access at the ordinary sites
with accepted HD adequacy, but it needs more evaluation and studies [123].
4. Children’s hemodialysis vascular access
Renal replacement treatment in children varies. According to North American Pediatric Renal
Trials and Collaborative Studies (NAPRTCS) registry of patients reaching ESRD in pediatric
centers, 25% submitted preemptive renal transplantation, 50% joined in peritoneal dialysis,
and 25% started hemodialysis [124, 125]. The preferable therapy is transplantation and in
perspective of a rather short time on HD, children receive maintenance HD through an
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indwelling CVC [126]. In the USA, no more than 800 pediatric patients receive maintenance
HD therapy, while the majority of smaller patients, less than 10 kg or 2 years old, receive
peritoneal dialysis [127–129].
However, hemodialysis can be performed successfully in infants and very young children, as
well [130]. An evaluation of the vasculature of children who will undergo hemodialysis will
indicate the appropriate vascular access. Because of the size of their vessels, there is limited
use of AVF in children, although there is an effort to make nephrology society to consider AVF
as the best access in pediatric HD patients [131]. According to a 2008 pediatric registry
(NAPRTCS) annual report, vascular access for hemodialysis included external percutaneous
catheter in 78% of patients, internal AV fistula in 12%, and internal and external AV shunt in
7.3 and 0.7%, respectively [125]. K/DOQI has encouraged greater use of AV fistulas in larger
children receiving hemodialysis who are not likely to receive a transplant within 12 months,
with a goal of achieving more effective dialysis with fewer complications than the ones
occurring with catheters. Patient’s size determines catheter size. An 8-F dual lumen catheter
is well tolerated in 4- to 5-kg children, and as the child’s size increases, a vascular access of
larger volume can be placed [132]. Blood flow in pediatric patients varies due to the catheter
size, which depends on the child’s size. In most of the patients, a recommended blood flow of
3 to 5 ml/kg/min is acceptable [133], providing adequate dialysis with Kt/V equal or greater
than 1.2. A recent study by Fadel et al. found a significant correlation between serum soluble
vascular cell adhesion molecule 1 and ESA doses in thrombosed AVF, and this could have
clinical significance after further investigation [134].
5. Vascular access morbidity and mortality
Studies have shown a mortality risk dependent on access type, with the highest risk associated
with central venous dialysis catheters, followed by AVGs and then AVFs [135–137]. Recently
Hicks et al. [137] stated that this benefit of AVG over TCs may not apply to younger (18–48
years) or older (over 89 years) age-groups. Additionally, patients who had a catheter as the
first VA had more complications and higher mortality [138]. The same results have been
presented by Ng et al. [139], who examined hospitalization burden related to VA type among
2635 incident patients. The risk for vascular access complications is increased in intensive HD,
with overall reported rates being lower in patients with AVF [140]. The CHOICE study
examined mortality based on access type in 616 hemodialysis patients for up to 3 years of
follow-up. Increased mortality was observed in CVCs and AVGs compared to AVFs in a rate
of 50% and 26%, respectively, with greater prevalence in male and elderly patients [141, 142].
Despite these findings and the KDOQI recommendations, dialysis access data from 2002 to
2003 showed that only 33% of prevalent hemodialysis patients in the USA were being dialyzed
via AVFs. On the contrary, in Europe and Canada, the majority of the patients [74% and 53%,
respectively) were being dialyzed via AVFs [143], but a decreasing trend in the use of AVF
seems to take place accompanied by an increasing trend in the use of TCs at the start and after
the start of HD [144].
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Vascular access admissions continue to fall, with more procedures now performed in an
outpatient setting, and are 45% below than in 1993. Among African American patients, the
relative risk of an all-cause hospitalization or one related to infection is almost equal to that of
Caucasians; the risk of a vascular access hospitalization, however, is 24% higher [145].
Thrombotic occlusion remains a major event, leading to permanent failure in 10% of AVFs and
20% of grafts each year. Interventional (percutaneous transluminal angioplasty and/or stent
implantation) or surgical revision of thrombosed accesses has similar outcomes with a high
rate of reinterventions. Diabetic elderly patients suffering from peripheral arteriosclerotic
obstructive disease are particularly prone to angioaccess-induced hand ischemia [146].
Patients with TCs and AVGs have higher chronic inflammation levels than those with AVFs
and increased requirements in epoetin [147]. In our previous work with 149 hemodialysis
patients with 202 vascular access procedures (177 Cimino-Brescia AVFs and 25 PTFE AVGs),
Cimino–Brescia fistula was used in all patients as the first choice vascular access, except for
one patient in the elderly group. Fifteen patients in the elderly group and 7 younger than 65
years old had PTFE AVGs as the third or second choice of VA, respectively. Vascular throm‐
bosis was the only reason of technique failure in both groups. Other complications were
aneurysms (10/48 and 14/101), infections (0/48 and 2/101) and edema (0/48 and 6/101) (Table
1). AVF had a 5-year technique survival in two groups of 35% and 45%, respectively (Figure
13). According to our findings, there was no difference in VA complications across age-groups
and the first AVF survival was independent of age [6]. Swindlehurst et al. [148] have published
similar results, according to which the creation of AVF in the elderly is not only possible but
also proved to have a short hospital stay, high patency rates, and an acceptable rate of further
intervention. The outcome of AVF benefits more from acknowledging individual vascular
conditions rather than age of the patient and therefore AVF creation should not be denied to
elderly patients [149]. Among patients over 80 years of age, the AVF as vascular access for HD
at the time of dialysis initiation was among the factors that benefit their survival [150].
Figure 13. Cumulative survival of first VA according to the patients’ age.
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Group A (age>60) Group B(age<60) P
Thrombosis 14/48 39/101 N.S.
Aneurysm 10/48 14/101 N.S.
Edema 0/48 6/101 N.S.
Infection 0/48 2/101 N.S.
Table 1. Complications of vascular access
According to the 2010 USRDS Annual Data Report, in 2008, hospitalizations increased, to a
point of 46% over 1993. Women on hemodialysis were 16% more likely to be hospitalized than
men, overall, in 2007–2008. Also, they had a greater risk than men of cardiovascular, infectious
and vascular access hospitalizations 11%, 14%, and 29%, respectively. Recently, in a retro‐
spective single-center analysis, our data varies to those we published in 1998. In 145 patients
on HD, we found that female had more possibilities to start HD with double lumen catheter
than male and also patients with heart failure independent of gender [115]. Patibandla et al.
[151] in their logistic regression model found that increasing age, female sex, black race, lower
body mass index, urban location, certain comorbidities and shorter pre-end-stage renal disease
nephrology care are all associated with a significantly lower like hood of AVF placement as
initial access predialysis. Additionally, there are geographic disparities in AVF creation with
decreased rates of AVF placement as the first access in metropolitan, but not rural, populations
compared with micropolitan communities [152]. Improvement in standardization of care
according to practice guidelines is necessary. AVF rate could be increased by improving access
to surgical resources and patients education [153]. Enhancing patient self-care abilities and
working together with patients on proper vascular access care can prolong vascular access site
viability [154]. Intraoperative blood flow measurements greater than 120 ml/min in AVF and
less than 320 ml/min in AVGs may be predictive factors of early failure and fistulography is
essential to access patency [155]. In addition to the clinical examination, there are numerous
radiological assessments of vascular access pre- and postoperative that enrich our diagnostic
armamentarium [156]. Recently, Remuzzi and Manini [157] presented a numerical model that
in the clinical setting should allow to reduce the incidence of AVF nonmaturation as well as
incidence of VA complications. Cannulation of VA is a crucial part of its management in HD
patients and the proper use of the rotating site technique might still be the best approach to
cannulation [158]. Evidence do not support the preferential use of buttonhole over rope-ladder
cannulation [159]. However, according to systematic review of Muir et al. [160], buttonhole
cannulation is associated with higher rates of infectious events, staff support requirements and
no reduction in surgical AVF interventions compared with rope ladder in home HD patients.
6. Nontunneled double lumen catheters complications
The nontunneled double lumen catheters’ complications concern the early ones during the
insertion and the late ones such as infection and thrombosis of the vessels.
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The severity of acute complications varies with the site of insertion. The lowest rate is in the
femoral position. A significant complication is perforation of the femoral artery. Bleeding
usually resolves within minutes of direct compression and large femoral or retroperitoneal
hematomas occur occasionally [161]. Subclavian insertion complications are more serious. The
overinsertion of guide wire can occasionally lead to atrial or ventricular arrhythmias, but they
are frequently transient [162]. The penetration or cannulation of the subclavian artery can lead
to hemothorax, which may require a thoracotomy tube. The incidence of pneumothorax varies
from less than 1% to more than 10% of insertions, depending on the skill and experience of the
physician. Pericardial rupture and tamponade also have been described [163, 164]. There is
less likelihood of arterial puncture or pneumothorax in ultrasound-guided catheter insertion
[165]. Subclavian insertion from the left has an increased risk of pneumothorax and atrial
perforation, which can be presented with acute hemopericardium upon initiation of dialysis.
Internal jugular vein is the preferred site of insertion because of subclavian stenosis and loss
of the ipsilateral arm for future hemodialysis access. This complication appears to occur more
often with subclavian (40–50%) than with internal jugular insertions (up to 10%) [166, 167]. At
internal jugular insertions, a carotid artery penetration may occur, but there is also a lower risk
of pneumothorax (0.1%). Post procedural chest X-ray is taken for confirmation of position of
catheter tip and to detect early complications, but delayed complications can occur after
catheterization. Thus, the patient should be monitored carefully and managed appropriately
according to the presenting signs and symptoms [168].
Prevention and treatment of catheter thrombosis are important clinical issues. To prevent
formation of thrombus, both lumens of the double lumen catheter are instilled with heparin
following hemodialysis [46]. Lytic agents such as urokinase and alteplase are effective in
treatment of catheter thrombosis. Alteplase has effectiveness rates in thrombosis treatment
comparable to the ones observed with urokinase [169]. Central vein catheters are associated
with the development of central vein stenosis [170]. The K/DOQI guidelines therefore recom‐
mend avoiding placement in the subclavian vein, unless no other options are available. If
central venous thrombosis is detected early, it responds well to directly applied thrombolytic
therapy [170] or to percutaneous transluminal angioplasty when the fibrotic stenosis can be
crossed with a guide wire [171]. The infection risks associated with temporary double lumen
catheters include local exit site infection and systemic bacteremia, both of which require
prompt removal of the catheter and appropriate intravenous antibiotic therapy [48, 172, 173].
Bacteremia generally results from either contamination of the catheter lumen or migration of
bacteria from the skin through the entry site, down the hemodialysis catheter into the blood
stream [174–176]. It seems that prevention strategies should target the first 6 months after
access placement or a remedial access-related procedure as over time the risk decline [177].
Skin flora, Staphylococcus and Streptococcus species, are responsible for the majority of infec‐
tions. It has been reported that surface modification with bismuth film reduces bacterial
colonization of nontunneled HD catheters [178]. Guidelines have been proposed by working
group with O’Grady et al. [179], with major areas of emphasis such as educating and training
healthcare personnel, who insert and maintain catheters, maximal sterile barrier precautions
during CVC insertion, using >0.5% chlorexidine. The use of prophylactic gentamicin/citrate
lock seems to be associated with a substantial reduction in catheter-related bloodstream than
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heparin [180]. Nurse is also a key figure in the preventions of such infections with the adoption
of standard precautions such as washing hands, managing HD rooms and other medical
devices, managing vascular access, and providing educational support to patient [181].
There is conflicting evidence concerning the risk of infection based on the site of insertion [172,
182, 183]. Coagulase-negative staphylococci, Staphylococcus aureus, aerobic gram-negative
bacilli, and Candida albicans most commonly cause catheter-related bloodstream infection. In
most cases of nontunneled CVC-related bacteremia and fungemia, the CVC should be
removed. The decision should be based on the severity of the patient’s illness, documentation
that the vascular-access device is infected, assessment of the specific pathogen involved and
presence of complications, such as endocarditis, septic thrombosis, tunnel infection, or
metastatic seeding [184].
Overall, compared with the subclavian vein, the internal jugular vein remains the preferred
access site in ambulatory patients. In the intensive care unit, either femoral or internal jugular
vein placement is satisfactory, with the use of ultrasound making internal jugular vein
placement safer.
The best solution is to prevent the infection by proper placement technique, optimal exit
site care and management of the catheter within the HD facility [46, 185]. It is generally
believed that CVC can adversely affect permanent VA ipsilateral placement outcomes due
to central vein stenosis that they cause, but it seems that the primary failure rate of AVF
and AVG is not affected by the presence of an ipsilateral catheter, but cumulative access
survival is inferior [186].
7. Arteriovenous fistulas complications
Early causes include inflow problems due to small or atherosclerotic arteries, or juxta-
anastomotic stenosis, so a preoperative evaluation for suitable access sites has to be performed
[187]. Selective use of duplex ultrasonography appears to enhance AVF success rate, although
agreed vessels criteria are needed [188]. It seems that the type of anesthesia plays a role in the
fistula surgery, with regional anesthesia having a beneficial sympathectomy like effect that
causes vasodilation with increased blood flow during surgery and in the AVF postoperatively
that may prevent early thrombosis and potentially improve outcome [189], but more evidence
are expected to establish this [190].
The etiology of this acquired lesion is not entirely clear but may be related to manipulating the
free end of the vein, torsion, poor angulation or loss of the vasa vasorum during anatomic
dissection. More often than not, this lesion can be effectively managed with angioplasty [191,
192] or surgical revision [193].
Accessory veins that divert blood flow from the intended superficial vessels to deeper conduits
or central venous stenoses due to prior TCs placements may cause outflow problems. Vessels,
smaller than one-fourth of the fistula diameter, are usually not hemodynamically relevant.
Juxta-anastomotic stenosis and accessory veins are the most common causes for early failure
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AVFs when preoperative evaluations for suitable access sites have been performed [187]. In
elderly population, there is an association of older age, female gender, black race, diabetes,
cardiac failure and shorter pre-ESRD nephrology care with predialysis AVF failure [194].
A rather rare complication secondary to bleeding from a catheter-related puncture of an AVF
is an acute forearm compartment syndrome [195].
Venous stenosis, thrombosis and attained arterial lesions like aneurysms or stenoses constitute
late causes of AVFs’ failure.
As blood flow decreases due to venous stenosis, weekly Kt/V ([dialyzer clearance time]/body
volume) decreases and/or recirculation increases, constituting great clinical signs of VA
dysfunction. AVF salvage surgery is of paramount importance in order to increase the patency
rate, which prolongs survival and increases the patient’s quality of life [196]. Balloon angio‐
plasty followed with stenting maintains the vessel lumen shape over time, as the stent is likely
to reduce the risk of restenosis that can otherwise occur after balloon angioplasty because of
the viscoelastic recoil of the vessel [197]. According to Aftab et al. [198], for AVF stenosis
resistant to conventional percutaneous transluminal angioplasty (PTA), cutting balloon
angioplasty may be a better second line treatment given its superior patency rates. It seems
that the deficiency of circulating endothelial progenitor cells is associated with early and
frequent restenosis after angioplasty of HD VA [199].
Native fistulas will not typically thrombose until flow is severely diminished. The thrombec‐
tomy of fistulas, although technically more challenging than in AVGs, is often successful and
if flow is reestablished, primary patency is longer than in grafts [200]. Antiplatelet treatment
protects fistula from thrombosis or loss of patency but has little or no effect on graft patency
and uncertain effects on vascular access maturation for dialysis and major bleeding [201].
Elective repair of subclinical stenosis in AVFs with blood flow >500 ml/min cost-effectively
reduces the risk of thrombosis and access loss [202]. Reconstructing the AVF by surgically
removing venous neointimal hyperplasia is an effective technique for late hemodialysis access
failure which preserves patients’ vessels [203].
As AVF’s size increases over time with increased blood flow, aneurysms may be formed,
constituting rather a cosmetic than functional concern, unless stenotic lesions accompany
them. If the overlying skin is atrophic or blanching, or there are signs of ulceration or bleeding,
a surgical evaluation must be performed urgently [204]. Also, if there is a high association of
venous outflow stenosis and AVF aneurysms, comprehensive therapy should encompass
treatment of any venous outflow stenosis before open AVF aneurysm repair. A two-stage
repair may decrease tunneled HD catheter use in patients with multiple aneurysms [205]. In
order to maintain an autogenous access while conserving future dialysis sites, partial aneur‐
ysmectomy is recommended as a first-line choice for managing aneurysm associated compli‐
cations [206]. Also, autologous surgical reconstruction is feasible in the majority of AVF
aneurysms. It preserves fistula function and keeps the advantages of an autogenous access
[207]. The rupture of such aneurysms in high-flow fistulas can lead to exsanguination and
death (Figure 14).
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Figure 14. Aneurysm in forearm AVF.
Infections of AVFs are rare but must be treated properly due to patients’ impaired immuno‐
logic status. Very rare infections of the AV anastomosis require surgery with resection of the
infected tissue. More often, infections occur at cannulation sites and then the arm should be
rested and cannulation cease [208]. In all cases of AVF infection, antibiotic therapy is initiated
with broad-spectrum vancomycin plus an aminoglycoside and converting to appropriate one
based on results of culture and sensitivities. Infections of primary AVFs should be treated for
a total of 6 weeks, analogous to subacute bacterial endocarditis [209].
8. Arteriovenous graft complications
AVGs have a functional life much shorter than AVFs. Neointimal hyperplasia causes venous
stenosis, which leads to thrombosis, and this is the natural course of AVGs. The principal cause
of thrombosis is the increased production of smooth muscle cells, myofibroblasts and vascu‐
larization within the neointima. Around the graft, there is also angiogenesis and numerous
macrophages in the tissue [210, 211]. Growth factors (GF) such as VEGF (vascular endothelial),
PDGF (platelet derived) and basic FGF (fibroblast) are present within the neointimal lesion
[211]. The presence of shear stress regulates vascular endothelium [212, 213] and that flow
within AVGs is likely to be different from native veins. Understanding the pathophysiology
of neointimal hyperplasia could lead to targeted therapy. Current studies are evaluating the
role of radiation [214], decoy peptides against transcription factors [215, 216] and local delivery
of drugs with cell-cycle inhibitory effects (e.g., paclitaxel [217] and sirolimus). Cell-based
strategies seek to take advantage of endothelial progenitor cells that release endogenous
inhibitors of proliferation and thrombosis, such as nitric oxide (NO) and prostacyclin [218].
Venous stenosis in AVGs leads to decreased blood flow and thrombosis, at a rate of 1–1.5 times/
patient/year [70]. Thrombosis is associated with anatomical stenosis, in most cases, which is
located in the venous anastomosis (60%), followed by the peripheral vein (37%) and within
the graft (38%) [219]. Stenosis and closure by venous anastomoses are the most frequent causes
of failure of AVG for hemodialysis. AVG closure can be addressed surgically and endovasc‐
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ularly (amenable to thrombectomy by radiological or surgical means) [220]. Percutaneous
angioplasty is safe and effective in treating venous stenosis [221], with a success rate of 80%
to 94% and primary patency around 60% at 6 months and 40% at 1 year. The placement of self-
expanding nitinol stents at the venous anastomosis appears to prolong patency in cases where
focal lesions are resistant to repeated angioplasty and recur and improve PTFE grafts longevity
in selected cases of older grafts [222]. Central stenosis is technically more difficult to treat, and
stenotic lesions often recur within 6 months [77]. Recently, a modular anastomotic valve device
(MAVD) has been in preliminary use in order to isolate the graft from the circulation between
dialysis sessions, decreasing the flow disturbances this way and as a result the intimal
hyperplasia [223]. During the last decades, percutaneous techniques became increasingly
important for the treatment of AVG failure [224]. Cutting balloon angioplasty is a safe and
effective treatment of graft to vein anastomotic stenosis, with significantly higher patency than
that of conventional balloon angioplasty [225]. From the point of view of Troisi et al. [226], the
combined simultaneous hybrid (open and endovascular) approach in urgency maximizes the
use of different available techniques, improving overall success rate to save a thrombosed graft.
As described above, AVGs’ thromboses are usually the result of multiple factors; such as
stenosis, hypotension and excessive compression for hemostasis. Hemodialysis nurses have
to be careful in order to avoid these factors. Thrombosis risk increases as blood flow (BF)
decreases, as May et al. [227] showed in their study. AVG thrombosis can be managed in an
outpatients’ basis endovascularly. Angiography for venous stenosis is always required and is
often accompanied by an angioplasty.
Prompt pharmaceutical thrombolysis or mechanical removal of the thrombus with a Fogarty
catheter and thromboaspiration or thrombectomy with a mechanical device [228] may avoid
a new catheter placement.
Infections of AVGs are severe complications and the second cause of vascular access loss.
Hemodialysis-related bacteraemia is 10-fold more often in AVGs than AVFs: 2.5 incidents
every 1000 HD sessions versus 0.2 [229]. It seems that the most significant modifiable risk factor
is patients’ hygiene [230].
A referral to surgeon of pseudoaneurysms for resection is imposed when they are increasing
rapidly in size, their width is more than 2-fold bigger than the graft, or the overlying skin seems
under duress (thin, bleeding, blanching) [231].
Ischemia, as a result of access placement, is more common for AVGs than AVFs: vascular steal
syndrome and ischemic monomelic neuropathy are two important clinical entities to distin‐
guish.
“Physiological” steal phenomenon occurs in 73% of AVFs and 90% of AVGs. Thus, in a
radiocephalic fistula, arterial blood from the palmar arch may also deliver blood into the
fistula. Unless there is the capacity for collateralization, this can lead to ischemia in the hand,
ranging from complaints about cold hands to necrotic fingertips. Most of these complaints
improve over time, but 1% of AVFs and up to 4% of AVGs require surgical revision [232].
Doppler ultrasonography is a useful adjunctive tool to determine the etiology of chronic
hemodialysis access-induced distal ischemia (HAIDI). Conservative measures combined with
close follow-up can be used as the first step in the management of chronic HAIDI patients with
mild symptoms [233]. Ischemic monomelic neuropathy is characterized by warm hands with
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a good pulse, but the hands are tender and swollen, usually immediately after surgery, and
there is muscle weakness [234]. The cause is likely ischemia of the nerves, and rapid surgical
reevaluation is needed. Wound and skin complications and greater incidence of thrombosis
of VA associated with recombinant human erythropoietin have been reported (rHuEPO) [235].
9. Tunneled catheter complications
Early or late catheter dysfunctions are the functional complications of TCs. Kinking and
unsuitable positioning of the catheter tip may be the cause of early dysfunction and can be
managed under fluoroscopic guidance. Around or at the catheter tip, fibrin sheaths and
thrombi can be formed constituting late causes of failure. Balloon angioplasty can disrupt
fibrinous sheaths, improving flow through a new catheter in the same location. Valliant et al.
[236] have demonstrate in their study that there is no significant increase in bacteraemia and
subsequent catheter dysfunction rates after fibrin sheath disruption by balloon procedure
compared to simple over the wire exchange. Symptomatic occlusions of the central veins
usually require the removal of the catheter and system anticoagulation and must be weighed
in the context of a continued need for dialysis and other available access options. Yoon et al.
recently referred a novel two-stage hemodialysis reliable outflow (HeRO) graft implantation
technique that avoids the use of a femoral bridging hemodialysis catheter in internal jugular
vein (IJV) catheter-dependent patients with contralateral central venous occlusion and thus
lowering the risk of infection related to a femoral catheter [237]. The use of catheter is related
to a higher incidence of infection and could compromise dialysis adequacy [238, 239]. Catheter-
related infections (CRI) are linked with increased all cause morbidity and mortality. The 8–
10% of MRSA bacteraemia in the UK occurs in patients receiving long-term hemodialysis. It
appears that the catheter locking with appropriate antimicrobial lock solutions (ALS) decrease
the infections’ incidence in HD patients [180, 240, 241]. It seems that prophylaxis with genta‐
micin of the catheter lumens reduces bacterial infection morbidity and mortality-related
bacteremia of catheter without obvious bacterial resistance, making such use advisable [242].
Even taurolidine–citrate–heparin catheter lock solution reduces staphylococcal bacteraemia
rates in HD patients [243] and improves the inflammatory profile in HD patients with TCs
[244]. Del Pozo et al. [245] in their prospective study showed that an evaluation of tunneled
catheters with intracatheter leukocyte culture helps in the early colonization of HD catheters,
giving the possibility to eradicate biofilm without the removal of catheter. Recent studies have
demonstrate that the “shower and no-dressing” technique appears to be a safe TC option that
improves quality of life [246, 247], although there is skepticism and uncertainty about the
appropriate dressing [248].
10. Final conclusions and remarks
Unfortunately, there are no revolutionary changes in the field of vascular access for hemo‐
dialysis in the last years. According to the guidelines, AVFs are still the best choice. Luckily,
AVGs’ survival has been increased, but still TCs are used in a great portion of ESDRD patients.
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As a result, humerobasilic and radiocephalic AVFs are the two VA types with the most
functioning longevity. However, AVFs’ primary patency rates at 1 year vary considerably
between USA and Europe. Hemodialysis patients with AVF seem to have lower mortality.
The incidence of AVFs has been effectively increased since the “fistula first” has been devel‐
oped, although it is accompanied with an increase in TCs.
AVGs as a second choice remain a good solution for patients without the possibility of AVF
and the survival of grafts has been improved.
TCs seem to be a new reality in most American and European dialysis units because of the
increase of number of elderly patients and with heart failure. Early referral to nephrologists
and patient’s education has an important role for a successful VA.
Additionally, the cannulation of VA is a crucial part of its management in HD patients and the
proper use may improve the survival of VA.
Summarized from the international literature and our experience, when there are suitable
vessels, the creation of AVF is of top priority. When this is not feasible or there is an AVF
failure, AVGs or TCs are the first choice alternative or the second best, respectively. Female
and old patients are more likely to initiate HD treatments via TC. A well-matured and
functioning permanent vascular access is of great importance for its longevity and thus early
referral to a nephrologist is mandatory.
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